Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025)

Candel Therapeutics (CADL) reported Long-Term Debt Repayments of -$4.2 million for Q4 2025, down 69.32% on a YoY basis from -$13.8 million in Q4 2024, and down 69.32% sequentially from -$2.5 million in Q3 2025.

Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends

Candel Therapeutics (CADL) has 2 years of Long-Term Debt Repayments data on file, last reported at -$4.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments fell 69.32% year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2025 stood at -$11.7 million (down 27.99% YoY), and the FY2025 full-year result was -$11.7 million, down 27.99% from the prior year.
  • Long-Term Debt Repayments retreated to -$4.2 million in Q4 2025, from -$2.5 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of -$1.7 million in Q1 2024 to a low of -$4.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 7.64 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Candel Therapeutics 542.51 Mn 542.51 Mn - -4.23 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -4.23 Mn
Dec 31, 2025 -4.23 Mn
Sep 30, 2025 -2.50 Mn
Sep 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Mar 31, 2024 -1.67 Mn
Mar 31, 2024 -1.67 Mn